CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao.

Pharming Group N.V. today confirmed it has been included in an injunction in the US obtained by CSL Behring, a subsidiary of CSL Limited of Australia (“CSL”), to prevent possible transmission of proprietary documents and data to Pharming which CSL claims have been removed from its systems by Dr Joseph Chiao, who was hired recently by Pharming to be a medical director.

CEO of Pharming Sijmen de Vries presented at the 21st Annual Global Life Science Investment Conference on the 9th of September in New York City.

Pharming Group N.V. announces it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).

Pharming Group N.V. presents its (unaudited) interim financial report for the first half year ended 30 June 2019.

Pharming Webinar: halfjaarcijfers 2019 donderdag 25 juli 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!

Pharming Group N.V. today announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. The presentation slides from today’s AGM are available on the Company’s website.

On 16 May each year, hereditary angioedema (HAE) patient organizations from around the world, led by the HAEi, the international umbrella organization for the world’s HAE patient groups, come together to support awareness of HAE; a rare, potentially life-threatening condition. hae day :-) aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need to lead a better life.

Pharming Group N.V. presents its (unaudited) interim financial report for the first quarter ended 31 March 2019.